LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) insider Stefan Galluppi acquired 3,000 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was acquired at an average cost of $4.93 per share, for a total transaction of $14,790.00. Following the completion of the transaction, the insider now directly owns 45,449 shares in the company, valued at approximately $224,063.57. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
LifeMD Stock Down 0.9 %
Shares of LFMD opened at $5.23 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.83 and a debt-to-equity ratio of 10.83. LifeMD, Inc. has a 1-year low of $4.05 and a 1-year high of $12.88. The firm has a fifty day simple moving average of $5.83 and a two-hundred day simple moving average of $7.93.
LifeMD (NASDAQ:LFMD - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The firm had revenue of $50.66 million during the quarter, compared to analysts' expectations of $48.47 million. During the same period last year, the business earned ($0.23) EPS. On average, equities research analysts expect that LifeMD, Inc. will post -0.49 EPS for the current year.
Institutional Investors Weigh In On LifeMD
I’m giving you the name of this investment for free
From Porter & Company | Ad
In this video I reveal one of the most powerful wealth secrets in American history.
One that has been buried in America’s legal system for the last 150 years.
But I believe this secret could also help you reclaim your dignity and freedom before it’s all taken away from you.
Watch now.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of LifeMD by 12.5% in the 1st quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company's stock worth $11,875,000 after purchasing an additional 128,701 shares in the last quarter. G2 Investment Partners Management LLC increased its stake in shares of LifeMD by 23.9% in the 4th quarter. G2 Investment Partners Management LLC now owns 688,050 shares of the company's stock worth $5,704,000 after purchasing an additional 132,850 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in LifeMD by 15.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 551,344 shares of the company's stock worth $3,782,000 after buying an additional 72,203 shares in the last quarter. Bank of New York Mellon Corp increased its stake in LifeMD by 63.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 234,583 shares of the company's stock worth $1,609,000 after buying an additional 91,183 shares in the last quarter. Finally, Squarepoint Ops LLC increased its stake in LifeMD by 23.8% in the 2nd quarter. Squarepoint Ops LLC now owns 154,390 shares of the company's stock worth $1,059,000 after buying an additional 29,692 shares in the last quarter. 35.52% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on LFMD shares. KeyCorp lowered their price objective on LifeMD from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Thursday, July 11th. Cantor Fitzgerald reiterated an "overweight" rating and set a $15.00 target price on shares of LifeMD in a research note on Tuesday, August 20th. Finally, B. Riley assumed coverage on shares of LifeMD in a research note on Friday, August 23rd. They set a "buy" rating and a $11.00 target price for the company. Six analysts have rated the stock with a buy rating, According to MarketBeat, LifeMD presently has a consensus rating of "Buy" and an average target price of $12.00.
View Our Latest Stock Analysis on LifeMD
About LifeMD
(
Get Free Report)
LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
